Fourth quarter and full year results 2022 and Annual Report 2022 publication
Investors Event Calendar
Novartis Annual Reporting Suite
Read and download our integrated report, annual regulatory filings, and other disclosures.
Environmental, Social and Governance (ESG)
ESG Updates: Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB) | Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB)
Latest updates: Investor Update on Access & Sustainability (PDF 1.6 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
January 09, 2023
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
December 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
September 03, 2021
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay connected to the latest news and information from Novartis.